Tirzema
Generic Name
Tirzepatide
Manufacturer
Global Pharma Inc.
Country
USA (or other primary manufacturing country)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tirzema 75 mg injection | ৳ 2,800.00 | N/A |
Description
Overview of the medicine
Tirzema 75 mg Injection contains Tirzepatide, a dual GIP and GLP-1 receptor agonist. It is used to improve blood sugar control in adults with type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Uses & Indications
Dosage
Adults
Starting dose is typically 2.5 mg subcutaneously once weekly. Dose may be escalated in 2.5 mg increments after 4 weeks, up to a maximum recommended dose of 15 mg once weekly. The 75 mg strength is not a typical single dose for Tirzepatide, as available strengths are up to 15 mg/0.5 mL. Please verify this specific strength (75 mg) with a healthcare professional.
Elderly
No dosage adjustment is recommended based on age; however, monitor renal function.
Renal_impairment
No dosage adjustment is recommended for patients with renal impairment (including end-stage renal disease); monitor renal function.
How to Take
Administer subcutaneously once weekly, at any time of day, with or without meals. Inject into the abdomen, thigh, or upper arm. Rotate injection sites. Do not mix with other injections.
Mechanism of Action
Tirzepatide activates both the GIP and GLP-1 receptors. GIP and GLP-1 are incretin hormones that are released from the gut in response to food intake. They stimulate insulin secretion in a glucose-dependent manner, reduce glucagon secretion, slow gastric emptying, and promote satiety, leading to improved glycemic control and weight reduction.
Pharmacokinetics
Onset
Within hours for initial glucose-lowering effects, sustained over weeks for full therapeutic effect.
Excretion
Mainly excreted via urine and feces after metabolic breakdown.
Half life
Approximately 5 days (around 120 hours).
Absorption
Slow absorption after subcutaneous injection, reaching peak plasma concentrations 24 to 48 hours post-dose.
Metabolism
Primarily metabolized by proteolytic cleavage, oxidation, and reduction, followed by conjugation.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to tirzepatide or any of the excipients.
- Not indicated for use in patients with type 1 diabetes mellitus.
Drug Interactions
Oral Contraceptives
May reduce the efficacy of oral contraceptives due to delayed gastric emptying. Advise patients using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation.
Insulin Secretagogues (e.g., sulfonylureas) or Insulin
Increased risk of hypoglycemia. Dose reduction of concomitant insulin secretagogues or insulin may be required.
Drugs that rely on threshold concentrations for efficacy
Due to delayed gastric emptying, Tirzema may impact the absorption of orally administered concomitant medications.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, the pen can be stored at room temperature (below 30°C/86°F) for up to 21 days.
Overdose
In case of overdose, symptoms may include severe gastrointestinal disturbances and hypoglycemia. Provide appropriate supportive treatment according to the patient's clinical signs and symptoms. Monitor glucose levels.
Pregnancy & Lactation
Pregnancy: Limited human data. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Unknown if Tirzepatide is excreted in human milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Tirzema and any potential adverse effects on the breastfed infant from Tirzema or from the underlying maternal condition.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to tirzepatide or any of the excipients.
- Not indicated for use in patients with type 1 diabetes mellitus.
Drug Interactions
Oral Contraceptives
May reduce the efficacy of oral contraceptives due to delayed gastric emptying. Advise patients using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation.
Insulin Secretagogues (e.g., sulfonylureas) or Insulin
Increased risk of hypoglycemia. Dose reduction of concomitant insulin secretagogues or insulin may be required.
Drugs that rely on threshold concentrations for efficacy
Due to delayed gastric emptying, Tirzema may impact the absorption of orally administered concomitant medications.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, the pen can be stored at room temperature (below 30°C/86°F) for up to 21 days.
Overdose
In case of overdose, symptoms may include severe gastrointestinal disturbances and hypoglycemia. Provide appropriate supportive treatment according to the patient's clinical signs and symptoms. Monitor glucose levels.
Pregnancy & Lactation
Pregnancy: Limited human data. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Unknown if Tirzepatide is excreted in human milk. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Tirzema and any potential adverse effects on the breastfed infant from Tirzema or from the underlying maternal condition.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Refer to the expiry date on the packaging, typically 2-3 years from manufacturing when stored correctly.
Availability
Pharmacies, hospitals, specialized clinics
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA)
Patent Status
Patented (currently under patent protection)
Clinical Trials
Extensive clinical trials (SURPASS and SURMOUNT programs) have demonstrated the efficacy and safety of tirzepatide in glycemic control for type 2 diabetes and for weight management, respectively.
Lab Monitoring
- HbA1c levels
- Blood glucose levels (fasting and postprandial)
- Renal function (e.g., serum creatinine, eGFR)
- Pancreatic enzymes (e.g., lipase, amylase) if pancreatitis is suspected
Doctor Notes
- Counsel patients on proper injection technique and storage.
- Educate patients on the signs and symptoms of pancreatitis and hypoglycemia.
- Emphasize the importance of adherence to diet and exercise.
- Review thyroid cancer risk with patients.
Patient Guidelines
- Follow diet and exercise recommendations from your healthcare provider.
- Learn how to properly inject Tirzema.
- Never share your Tirzema pen with others, even if the needle is changed, as this carries a risk of infection.
- Store the pen in the refrigerator. Protect from light.
Missed Dose Advice
If a dose is missed, administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. Do not administer two doses within 48 hours.
Driving Precautions
Tirzema itself is unlikely to affect the ability to drive or operate machinery. However, if used in combination with insulin or sulfonylureas, the risk of hypoglycemia increases, which may impair driving ability. Patients should be aware of their blood glucose levels.
Lifestyle Advice
- Maintain a balanced diet and regular physical activity to optimize blood sugar control and weight management. Hydrate adequately.
- Monitor for symptoms of hypoglycemia if used with insulin or sulfonylureas.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tirzema Brand
Other medicines available under the same brand name
